Some interesting back and forth on Yahoo message board, food for thought!
Johnny D2 hours ago
What could the insider buying possibly mean??
I think HEB and the FDA have struck a deal. What we know: Ampligen is still the only game in town for CFS (Rituximab held promise, but failed), Argentina has approved Ampligen using the same data (plus some) that the FDA rejected. Don't let Tom convince you that Argnetina was some mickey mouse approval -- their approval system closely aligns with the EU system of approval - it's a very big deal. The FDA approved a price increase for ampligen a year or so ago - very telling - the FDA obviously wants hemispherx to succeed. Hemispherx is now producing commercial sized batches of ampligen - another big deal -- they are not only doing one commercial batch, of what 8500 vials, only 2100 of which they have sold (MyTomorrows), but they are doing a 2nd commercial batch, that will be ready in July. No way that between Kalinski's cancer trials and Argentina's non-existent CFS program (MyTomorrow's is already taken care of!) do they need this quantity of drug!
The interesting thing to see --- what form will HEB's deal with the FDA take? If HEB found a big pharma partner to spring for 30 million to do another Phase 3 trial, that would be one way. The conventional way. I don't think this has happened. Big pharma wouldn't touch CFS in the past, why would they now? CFS folks need this drug now, they have needed this drug for the last 30 years. Patients, clinicians, CFS experts have been asking and lobbying for approval for years. IMO, it will be a conditional approval (HEB knows which patients benefit), and the last demand from the FDA has been met - which was, can you produce commercial size batches of this drug, enough drug to satisfy big demand?
Tom is just going to LOVE this!
LOL
william 02 hours ago
Like your thinking but back to the insiders and their quick decision to purchase ALL their outstanding 2028 expiry options allotted to them tells me they likely have a definitive offer of a buyout. That would not be front running just exercising their options, which they did down to the last share. The market caps so low that offering double the cost per share at markets close Friday would be nothing for a deep pocket biotech company that can do all the FDA required research needed.
There's more to the reason of this all in option sweep buyup as 2028 is nearly a decade out from their buy yesterday. You don`t throw $364,982.00 at your options in mass hoping to move the shares price!
Also remember the 1MM plus daily shares exchanging back and forth of late? Shares went from weak hands to new acquirer to establish a majority stake!!!!!!
